For Research Use Only. Not for use in diagnostic procedures.
Advancing Molecular Research in HCV Genotyping
ABL Diagnostics offers one of the most complete and innovative portfolios for Hepatitis C Virus (HCV) genotyping and drug resistance testing, combining its proprietary DeepChek® technology with the VELA Sentosa™ HCV assays. Together, these solutions empower laboratories with flexible and robust workflows for Sanger and Next Generation Sequencing (NGS)–based applications.
DeepChek® HCV Portfolio — Precision through Sanger & NGS Sequencing
The DeepChek® HCV assays are designed for accurate genotyping, subtyping, and resistance detection across NS3, NS5A, NS5B, Core, and 5′UTR regions, supporting both Sanger and NGS platforms.
Key Assays:
- DeepChek® HCV NS5B + 5′UTR Genotyping Assay V3 — Dual-region amplification for high-resolution genotyping and subtyping
- DeepChek® HCV NS5A DR Assay — Detects resistance to NS5A inhibitors
- DeepChek® HCV NS3 Genotyping and DR Assay — Determines NS3 inhibitor susceptibility
- DeepChek® HCV Core Genotyping Assay — Designed for accurate genotyping and subtyping in research settings using plasma or serum samples.
- DeepChek® HCV NS5B Genotyping and DR Assay — Targets NS5B resistance mutations
Highlights:
- Pangenotypic coverage across all HCV genotypes
- Low limit of detection (LoD): as low as 1000 IU/mL
- Optimized for use with both Sanger and NGS workflows in research applications.
- Flexible throughput: from 1 to 384 samples/run
- CE-IVD certified software and automation ready
The DeepChek® Software completes the ecosystem, offering secure, browser-based analysis with automated genotyping, subtyping, resistance interpretation, and customizable clinical reporting. Hosting options include local installation or HDS-compliant Cloud.
VELA Sentosa™ HCV Solutions — Integrated Automation for Streamlined Workflows
As the exclusive EMEA distributor for VELA Diagnostics, ABL Diagnostics proudly offers Sentosa™ HCV assays for laboratories seeking fully automated and standardized NGS workflows.
Sentosa™ SQ HCV Genotyping Assay V2
→ Provides accurate HCV genotype and subtype determination from plasma or serum samples using the Sentosa™ SX Series and SQ Series systems.
- Seamless sample-to-answer automation
- NGS-based pangenotypic genotyping
- High reproducibility and sensitivity
ViroKey™ SQ Flex Genotyping Assay
→ A flexible, open NGS solution allowing HCV genotyping within a customizable multiplex workflow.
- Enables targeted sequencing for multiple viral pathogens
- Compatible with the Sentosa™ SQ Platform
Adaptable for research or diagnostic settings
One Unified Portfolio — Enabling Comprehensive Molecular Analysis for Research
By combining the DeepChek® assays and software with the VELA Sentosa™ automation and NGS platforms, ABL Diagnostics provides an end-to-end workflow for HCV molecular research — from extraction to data analysis.
Key Benefits:
- Comprehensive portfolio
- Integrated automation and analysis
- High sensitivity and accuracy
- Cloud or on-premise data security
Designed to support cost-efficient workflows for varying research throughput needs.